The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth), can reduce tumor sizes in patients with bladder cancer see http://clinicaltrials.gov/ct2/show/study/NCT00661609
- 11/21/11 11/21/11 -
- 3/27/14 3/27/14 - Martin Dugas
- 9/17/21 9/17/21 -
- 9/27/21 9/27/21 - Sarah Riepenhausen
September 27, 2021
To request one please log in.
Creative Commons BY 4.0